Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating gout and preparation method thereof

A composition and drug technology, applied in the field of gout treatment drugs and their preparation, can solve problems such as liver and kidney function damage, hemolytic anemia, anaphylactic shock, etc., and achieve the effects of accelerating uric acid metabolism, increasing muscle synthesis, and reducing joint pain.

Active Publication Date: 2020-12-29
乐康珍泰(天津)生物技术有限公司 +1
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are many drugs for the treatment of gout on the market, including colchicine, sunflower alkaloids, allopurinol, probenecid and other drugs. A series of side effects such as anaphylactic shock, some plant alkaloids can neutralize uric acid, but patients experience increased pain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating gout and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] A pharmaceutical composition for the treatment of gout, the functional ingredients are composed of euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, among which Euglena β-1 ,3-glucan 26.5%, compound active alkaloid 29.4%, deep-sea fish peptide 7.2%, small molecule potassium hyaluronate 3.5%, D-glucosamine ketone glutarate 8.6%, glutamine 4.1%, L -Alanine 3.0%, L-Arginine 4.2%, L-Methionine 3.5%, L-Lysine 3.5%, L-Leucine 6.0%, Vitamin C 0.5%.

[0018] The above-mentioned pharmaceutical composition for treating gout is made into a powder (5g / bag), and the specific steps of the preparation method are as follows:

[0019] (1) Weigh euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 30...

Embodiment 2

[0022] A pharmaceutical composition for the treatment of gout, the functional ingredients are composed of euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, among which Euglena β-1 , 30% 3-glucan, 15% complex active alkaloids, 15% deep-sea fish peptide, 5% small molecule potassium hyaluronate (molecular weight less than 3000), 5% D-glucosamine ketoglutarate, glutamine Amide 5%, L-alanine 5%, L-arginine 3%, L-methionine 2%, L-lysine 3%, L-leucine 9%, vitamin C 1%.

[0023] The preparation method refers to Example 1.

Embodiment 3

[0025] A pharmaceutical composition for the treatment of gout, the functional ingredients are composed of euglena β-1,3-glucan, complex active alkaloids, deep-sea fish peptides, small molecule potassium hyaluronate (molecular weight less than 3000), D-amino Glucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, among which Euglena β-1 ,3-glucan 18%, complex active alkaloid 35%, deep-sea fish peptide 3%, small molecule potassium hyaluronate (molecular weight less than 3000) 2%, D-glucosamine ketoglutarate 10%, glutamine Amide 3%, L-alanine 2%, L-arginine 6%, L-methionine 5%, L-lysine 6%, L-leucine 5%, vitamin C 0.2%.

[0026] The preparation method refers to Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for treating gout and a preparation method thereof. The pharmaceutical composition is prepared by mixing the following active components in parts byweight: 18-30 parts of euglena gracilis beta-1,3-glucan, 15-35 parts of complex active alkaloid, 3-15 parts of deep sea fish peptide, 2-5 parts of small molecular potassium hyaluronate, 5-10 parts ofD-glucosamine ketoglutarate, 3-5 parts of glutamine, 2-5 parts of L-alanine, 3-6 parts of L-arginine, 2-5 parts of L-methionine, 3-6 parts of L-lysine, 5-9 parts of L-leucine and 0.2-1 parts of vitamin C. The pharmaceutical composition can effectively improve and treat gout and other metabolic arthritis, rheumatic arthritis, rheumatoid arthritis and other chronic diseases, repair joints, reduce arthralgia, increase muscle synthesis and accelerate uric acid metabolism.

Description

technical field [0001] The invention relates to a drug for treating gout and a preparation method thereof, in particular to a pharmaceutical composition for treating gout and a preparation method thereof. Background technique [0002] Gout is a group of heterogeneous chronic metabolic diseases caused by purine metabolism disorders, and its clinical features are hyperuricemia, recurrent gouty acute arthritis, interstitial nephritis and tophi formation; severe cases are accompanied by joint deformities or uric acid urolithiasis. The clinical features of gout are: hyperuricemia; recurrent gouty acute arthritis; tophi formation and deposition of tophi chronic arthritis; joint deformity, etc. [0003] The formation of ventilation is mainly caused by the excessive accumulation of uric acid. The main reasons for the accumulation of uric acid are: excessive consumption of high-purine foods, problems with purine metabolism in the body, too little excretion, and uric acid cannot be e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/01A61K31/716A61K31/78A61K31/198A61K31/375A61K31/7008A61P19/06A61P19/02A61P29/00
CPCA61K31/716A61K38/012A61K31/78A61K31/198A61K31/375A61K31/7008A61P19/06A61P19/02A61P29/00A61K2300/00Y02A50/30
Inventor 徐庆阳李志华熊海波张宁杨柳
Owner 乐康珍泰(天津)生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com